Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Darren Pan

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Blood Advances|August 26, 2022
Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myelomaTarek H Mouhieddine, Oliver Van Oekelen, David T Melnekoff, et al.
JCI Insight|May 5, 2026
Detection of cytokine release syndrome using wearables and cytokine profiling following CAR-T therapy for myelomaSridevi Rajeeve, Matt Wilkes, Nicole Zahradka, et al.
Blood Advances|May 22, 2024
Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myelomaMateo Mejia Saldarriaga, Darren Pan, Caitlin Unkenholz, et al.
Blood|August 1, 2025
Sequential Targeting in Multiple Myeloma: Talquetamab, a GPRC5D bispecific antibody, as a Bridge to BCMA CAR-T cell therapyBinod Dhakal, Othman Salim Akhtar, David Fandrei, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Blood Advances|August 26, 2022
Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myelomaTarek H Mouhieddine, Oliver Van Oekelen, David T Melnekoff, et al.
JCI Insight|May 5, 2026
Detection of cytokine release syndrome using wearables and cytokine profiling following CAR-T therapy for myelomaSridevi Rajeeve, Matt Wilkes, Nicole Zahradka, et al.
Blood Advances|May 22, 2024
Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myelomaMateo Mejia Saldarriaga, Darren Pan, Caitlin Unkenholz, et al.
Blood|August 1, 2025
Sequential Targeting in Multiple Myeloma: Talquetamab, a GPRC5D bispecific antibody, as a Bridge to BCMA CAR-T cell therapyBinod Dhakal, Othman Salim Akhtar, David Fandrei, et al.
Pageof 3